Corporation Plc. I 3 Executive Summary Summary of the Company and its subsidiaries’ operating results for the quarter ended December 31st, 2018 Unit: THB Million Q4/2017 (Restate) Q3/2018 Q4/2018 YoY QoQ 2017
and conditions of SET. 2 2. Approved the interim dividend payment of the Company based on the Company’s operating results of the period 1 January 2019 – 31 March 2019, to shareholders at the rate of THB
the amount included expenses related to Asia Can Manufacturing (“ACM”) which is currently under the construction, machine installation and system preparation process before the commercial plan in 4Q
fibersol, L-carnitine and vitamin B, and Peptein Gold, a drink containing natural superfoods which provide anti-aging properties, boost the immune system and reduce inflammation. Personal Care Segment Total
Flow from Operating 255.4 188.0 Cash Flow from Investment (932.9) (2.9) Cash Flow from Financing (0.4) 0.0 Net Cash Flow 820.0 1,250 (Unit : THB mn) The Company has net cash flow as at 31st March, 2018
“SORKON” and its subsidiaries (“the company”) would like to clarify the operating results for Quarter 1/2018 as follows: Revenue and Net Sales The Company recorded its total revenue of Baht 696.5 million
Company Limited and its subsidiaries (“the Company”) would like to clarify herewith the operating result for the year 2018 as follows:- Financial Position As at 31 December 2018, total consolidated assets
. DOD2019/004 February 20, 2019 Subject: Management’s discussion and analysis of the Company’s operating results for the year 2018 period To: President The Stock Exchange of Thailand DOD Biotech Public
Public Company Limited Management Discussion and Analysis Operating Results for the period year ended 31 December 2018 Page 2 of 4 T.K.S. TECHNOLOGIES \ THB million Y18 Y17 %Chg As Reported (% to Sales
RP-AC 001/2019 February 26, 2019 Subject Clarification of 2018 Operating Results To Directors and Managers of the Stock Exchange of Thailand Richy Place 2002 Public Company Limited (RICHY) would like